|Description||This active molecular is a selective RON receptor tyrosine kinase inhibitor. The RON receptor tyrosine kinase has been reported that it usually overexpressed in the pancreatic cancer. Preclinical research shows that inhibition of RON function can decrease pancreatic cancer cell migration, invasion and survival and this can also sensitize pancreatic cancer cells to chemotherapy. RON receptor tyrosine kinase may become a potential therapeutic target for the pancreatic cancer.|
|Synonyms||LCRF-0004; LCRF 0004; LCRF0004; N-(3-fluoro-4-((2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
Crizotinib is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor.
Savolitinib is a tyrosine kinase inhibitor with potential anticancer activity.
This active molecular is a selective RON receptor tyrosine kinase inhibitor. The RON receptor tyrosine kinase has been reported that it usually overexpressed in...
c-Met inhibitor 1
c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic can...
Tyrosine kinase inhibitor
It is a Tyrosine kinase inhibitor.
Lys05, a water-soluble salt of Lys01, is a selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively, resulting...
CEP-40783 is an orally-active, nanomolar potent and highly kinase-selective Type II inhibitor of the AXL and c-Met RTK with IC50 values of 7 nM and 12 nM, respe...
Capmatinib, also known as INCB28060 and INC280, is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with...